Reuters logo
3 months ago
BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb
April 13, 2017 / 11:51 AM / 3 months ago

BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb

1 Min Read

April 13 (Reuters) - Biogen Inc:

* Biogen Inc - under agreement, biogen will receive worldwide rights to BMS-986168

* Biogen Inc - Biogen will be responsible for full development and global commercialization of bms-986168 in ad and psp

* Biogen Inc - to assume all remaining obligations to former stockholders of Ipierian, Inc related to Bristol-Myers Squibb's acquisition of company in 2014

* Biogen Inc - may pay up to $550 million in remaining milestones plus royalties including a near term $60 million milestone

* Biogen Inc - announced an agreement to exclusively license BMS-986168 from Bristol-Myers Squibb Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below